



Cite this: *RSC Adv.*, 2019, 9, 17913

# Bifunctional nano-Ag<sub>3</sub>PO<sub>4</sub> with capabilities of enhancing ceftazidime for sterilization and removing residues†

Yahui Zhang,<sup>‡,ab</sup> Xiaochen Zhang,<sup>‡,a</sup> Ruiming Hu,<sup>\*c</sup> Yang Yang,<sup>a</sup> Ping Li<sup>a</sup> and Qingsheng Wu<sup>id \*a</sup>

Since the efficacy of antibiotics towards bacteria is decreasing over time, the rising of antibiotic emission has become an increasingly grave issue. In this study, we proposed an integrated antibacterial nanotechnology without pollution residues, which synergistically enhances the antibacterial activity of ceftazidime by using the inorganic nano-Ag<sub>3</sub>PO<sub>4</sub>, and subsequently removes drug residues by photocatalysis. Ag<sub>3</sub>PO<sub>4</sub> were synthesized using a simple ion-exchange method without any reducing agent or protectant. The combined antibacterial activity of Ag<sub>3</sub>PO<sub>4</sub> and 22 kinds of antibiotics against *Escherichia coli* was first studied. The results showed that Ag<sub>3</sub>PO<sub>4</sub> and ceftazidime exhibited the best synergistic effect. Next, the synergy mechanism was proposed, the non-chemical bond forces between Ag<sub>3</sub>PO<sub>4</sub> and ceftazidime was determined by zeta potential analyzer, X-ray photoelectron spectroscopy (XPS) and infrared spectroscopy (IR). The interaction between antimicrobials and bacteria was further demonstrated by surface plasma resonance spectroscopy (SPR), scanning electron microscopy (SEM) and propidium iodide (PI) staining. In addition, the production of reactive oxygen species (ROS), the induction of oxidative stress and dissolution of silver ions in Ag<sub>3</sub>PO<sub>4</sub> were studied and found out that only under light, could the ROS be generated. In conclusion, the synergistic effect of Ag<sub>3</sub>PO<sub>4</sub> and ceftazidime is responsible for the joint destruction of cell wall.

Received 14th March 2019  
 Accepted 15th May 2019

DOI: 10.1039/c9ra01969c

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Since penicillin was discovered by the British bacteriologist in 1928 for the first time,<sup>1</sup> there have been thousands of antibiotics, and hundreds of them are commonly used in the clinical practice. However, due to the resistance of bacteria, many of those antibiotics are no longer effective. However, the development of antibiotics is usually limited by genomic data, technology and innovation.<sup>2</sup> At present, antibiotics were mostly abused in agriculture, aquaculture and animal husbandry.<sup>3</sup> These antibiotics accumulated in animals, fish and crabs might further transmitted to human by consuming animal food. Excessive antibiotics might also transfer into the water cycle and further threat to public health.<sup>4</sup>

The development of nanotechnology has led people to pay attention to the anti-infective effect of inorganic metal particles.<sup>5-7</sup> Here, we proposed a synergistic system of inorganic nanoparticles enhancing the efficacy of traditional organic antibiotics. Since the synergistic antibacterial effect of silver and amoxicillin has been reported in 2005,<sup>8</sup> the synergistic effect of nanoparticles and other antibiotics were reported successively.<sup>9-12</sup> Ag<sub>3</sub>PO<sub>4</sub> is a promising antibacterial agent,<sup>13,14</sup> and more importantly is regarded as a significant breakthrough in the field of visible-light-driven photocatalysts.<sup>15,16</sup> Wu *et al.*<sup>17</sup> and Liu *et al.*<sup>18</sup> synthesized Ag<sub>3</sub>PO<sub>4</sub> with different morphologies and studied its antibacterial activity. Other researchers have improved the antibacterial activity of Ag<sub>3</sub>PO<sub>4</sub> by doping graphene.<sup>19,20</sup> Huang *et al.*<sup>21</sup> and Gan *et al.*<sup>22</sup> combined CoFe<sub>2</sub>O<sub>4</sub> with Ag<sub>3</sub>PO<sub>4</sub> to improve its photocatalytic property. Chen *et al.*<sup>23</sup> and Yan *et al.*<sup>24</sup> increased the photocatalytic performance of Ag<sub>3</sub>PO<sub>4</sub> by adding In<sub>2</sub>O<sub>3</sub> or In<sub>2</sub>S<sub>3</sub>. However, the combined antibacterial activities of Ag<sub>3</sub>PO<sub>4</sub> and antibiotics have not been studied.

In this study, we designed a non-polluting synergistic antibacterial nanotechnology that not only synergistically enhances the efficacy of ceftazidime by Ag<sub>3</sub>PO<sub>4</sub>, but also photocatalytically degrades the drug residues. To elucidate the synergistic mechanism, the interaction of Ag<sub>3</sub>PO<sub>4</sub> with ceftazidime was tested, as well as the interaction of antimicrobials (both Ag<sub>3</sub>PO<sub>4</sub> and ceftazidime) with bacteria. This non-polluting antibacterial nanotechnology is expected to benefit human health and the water environment.

<sup>a</sup>School of Chemical Science and Engineering, School of Life Science and Technology, Shanghai Key Laboratory of Chemical Assessment and Sustainability, Tongji University, Shanghai 200092, China. E-mail: [qswu@tongji.edu.cn](mailto:qswu@tongji.edu.cn); Tel: +86-21-65982620

<sup>b</sup>Taiyuan Environmental Science Research Institute, Taiyuan 030002, China

<sup>c</sup>Huashan Hospital, Fudan University, Shanghai 200040, China. E-mail: [ruiminghu7@163.com](mailto:ruiminghu7@163.com)

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra01969c

‡ Both authors contribute equally to this work.



## Experimental

### Materials

Standard strain of *Escherichia coli* (ATCC 25922) was supplied from Shanghai Tenth People's Hospital. Silver nitrate ( $\text{AgNO}_3$ ) and disodium hydrogen phosphate ( $\text{Na}_2\text{HPO}_4$ ) were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). 3-Mercaptopropionic acid (MPA) and *N*-(3-dimethylamino-propyl)-*N'*-ethylcarbodiimide hydrochloride (EDC) were purchased from Aladdin (Shanghai, China). *N*-Hydroxysuccinimide (NHS), propidium iodide (PI) and 2',7'-dichloro-fluorescein diacetate (DCFH-DA, 97%) were purchased from Sigma-Aldrich (Shanghai, China). Susceptibility paper and Luria-Bertani (LB) culture medium were purchased from Microbial Reagent Co. Ltd. (Hangzhou, China). Ceftazidime (CAZ) powder was purchased from Mengry Bio-Technology Co. Ltd. (Shanghai, China).

### Preparation of nano- $\text{Ag}_3\text{PO}_4$ and $\text{Ag}_3\text{PO}_4$ -CAZ complex

Nano- $\text{Ag}_3\text{PO}_4$  was prepared by ion exchange method.<sup>25</sup> 10 mL 0.4 M  $\text{AgNO}_3$  was added into 10 mL 0.15 M  $\text{Na}_2\text{HPO}_4$  dropwise. After 30 min reaction, the yellow precipitate was washed with deionized water and ethanol several times, and then dried in vacuum at 60 °C overnight. For synthesis of  $\text{Ag}_3\text{PO}_4$ -CAZ complex, 100 mg  $\text{Ag}_3\text{PO}_4$  was mixed with 100 mg ceftazidime (CAZ) in 4 mL water. After ultrasonic oscillations for 30 min, the mixtures were washed with deionized water for several times, and then freeze drying overnight.

### Evaluate antibacterial activities by disk diffusion test

Several bacterial colonies were inoculated to 50 mL LB broth and incubate in shaker overnight. Then the bacteria solution was diluted to about  $1 \times 10^8$  CFU  $\text{mL}^{-1}$  ( $\text{OD}_{600} = 0.1$ ). 100  $\mu\text{L}$  tenfold diluted suspension ( $10^7$  CFU  $\text{mL}^{-1}$ ) was equably coated on every LB agar plate. The drug sensitive slips (diameter 7 mm) were attached on it. 10  $\mu\text{L}$   $\text{Ag}_3\text{PO}_4$  (10, 100, 1000 mg  $\text{L}^{-1}$ ) solution was added on slip, respectively. After incubated at 37 °C for 20 h, the inhibition zone diameters were measured. All experiments were repeated at least three times to eliminate error.

### Characterization of the synergistic antibacterial system

X-ray diffraction (XRD) patterns were recorded by a Bruker D8 Advanced X-ray diffractometer with a  $\text{Cu K}\alpha$  (1.5 Å) source. Field scanning electron microscopy (SEM) images were obtained with a Hitachi S-4800 SEM. The absorbance (OD) values of bacteria solution were measured by Agilent UV-Vis 8453 Ultraviolet-visible spectrometer. Particles surface charges were analyzed by Malvern Zetasizer Nano ZS90 dynamic light scattering instrument (DLS). The surface elements of the samples were conducted by Kratos AXIS Ultra DLD X-ray Photoelectron Spectroscopy (XPS). Sample functional groups were recorded using Nicolet NEXUS 6700 Fourier transform infrared (FTIR) spectrometer. Fluorescence spectra of the samples were collected by Hitachi F-7000 Fluorescence spectrophotometer.

### Surface plasmon resonance (SPR) analysis of the interactions between micro/nanoparticles and bacteria

SPR experiments were performed with Reichert SR7500DC dual channel SPR instrument. Specific experimental procedures can be referred to the previous study.<sup>26</sup> Briefly, the naked sensor chips were activated by piranha solution, then the carboxyl groups were linked through MPA solution, EDC/NHS solution was used to excite carboxyl terminal, finally  $\text{Ag}_3\text{PO}_4$  and  $\text{Ag}_3\text{PO}_4$ -CAZ were attached. After finished these pretreatment process, a series of bacteria solution ( $1.25 \times 10^7$ ,  $2.5 \times 10^7$ ,  $5 \times 10^7$ , and  $1 \times 10^8$  CFU  $\text{mL}^{-1}$ ) successively flowed over the sensory chip surface. The equilibrium dissociation constant ( $K_D$ ) was calculated by ClampXP software.

### SEM analysis to observe cell morphology

The *E. coli* cells were transferred into 50 mL LB medium with optical density (OD) around 0.1. After incubation in the shaker at 37 °C, 150 rpm, until the  $\text{OD}_{600}$  value reached 0.6. The bacteria solution was dispensed into test tubes with 3 mL of each tube. 300  $\mu\text{L}$   $\text{Ag}_3\text{PO}_4$  solution, 300  $\mu\text{L}$  ceftazidime solution were added alone or in combination (with final concentration as 10, 100, 1000 mg  $\text{L}^{-1}$ ), incubated at 37 °C, 200 rpm for 4 h on a shaker bed. The above test tubes were centrifuged at 8000 rpm for 3 min, then collected cells were immobilized by 5 mL 2.5% glutaraldehyde (diluted with PB buffer) for 2 h, subsequently washed with PB three times. The dehydration was accomplished with graded ethanol (30%, 50%, 75%, 85%, 95%, and 100%) for 20 min each. Then the cells were dispersed in 1 mL ethanol, and 20  $\mu\text{L}$  of the cells were dripped onto a silicon wafer. After freeze-drying overnight, cell morphology was observed by SEM.

### Assays for membrane integrity

The bacteria cells were transferred into 50 mL LB broth until the  $\text{OD}_{600}$  value reached 0.1. Then it was incubated in the shaker until the  $\text{OD}_{600}$  reached 0.5. The bacteria solution was dispensed into test tubes with 3 mL of each. After added with  $\text{Ag}_3\text{PO}_4$ , ceftazidime alone or jointly the tubes were incubated at 37 °C, 200 rpm for 3 h, and each sample was centrifuged at 10 000 rpm for 2 min. Harvested cells were stained with 5 mL 5  $\mu\text{M}$  propidium iodide (PI) in the dark for 20 min. After centrifuged at 10 000 rpm for 2 min, 3 mL phosphate buffered saline (PBS) was used to disperse bacteria. Finally, the samples were analyzed on a spectrofluorometer with excitation wavelength of 535 nm, emission wavelength of 600 nm.

### Determination of reactive oxygen species (ROS)

To determine the ROS content generated by  $\text{Ag}_3\text{PO}_4$ , 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO) was used as the radical trap.  $\text{Ag}_3\text{PO}_4$  suspension with DMPO was analyzed by Bruker EMX electron paramagnetic resonance (EPR) spectrometer. To simulate daylight environment,  $\text{Ag}_3\text{PO}_4$  suspension was exposed to xenon lamp for 20 min before measurement. Next, intracellular ROS levels were also determined. The bacteria cells were transferred into 50 mL LB broth until the  $\text{OD}_{600}$



value reached 0.1. After incubated in the shaker at 37 °C, 150 rpm for 2.5 h, the suspension was centrifuged at 10 000 rpm for 2 min. Then 60 mL 10 μM 2',7'-dichloro-fluorescein diacetate (DCFH-DA) was used to stain cells for 20 min in the dark. After washed with PBS twice, harvest cells were resuspended in PBS with OD<sub>600</sub> about 0.5. Next, the test tubes were added with 3 mL above-mentioned bacteria solution. The samples were then treated with Ag<sub>3</sub>PO<sub>4</sub>, ceftazidime alone or jointly for 2 h, at 37 °C, 200 rpm. At last, the samples were analyzed on a spectrofluorometer with an excitation wavelength of 488 nm, emission wavelength of 520 nm.

### Detection of metal ion release

100 mg L<sup>-1</sup> Ag<sub>3</sub>PO<sub>4</sub> was mixed with 100 mg L<sup>-1</sup> ceftazidime in LB broth. All tubes were incubated at 37 °C, 150 rpm. The samples were centrifuged at 10 000 rpm for 10 min after 0.5, 2, 6, 12 and 24 h. 1 mL supernatants of each tube were digested with 1 mL HNO<sub>3</sub>, 1 mL H<sub>2</sub>O<sub>2</sub> for 30 min at 100 °C.

After the liquid cooled down, all samples were diluted with 2% HNO<sub>3</sub> to 12 mL. The silver ion content was measured by Agilent 720ES inductive-coupled plasma (ICP) optical emission spectrometer.

### Photocatalytic degradation experiments

The prepared ceftazidime solution was added into 25 mL different concentrations of Ag<sub>3</sub>PO<sub>4</sub> aqueous solution. After ultrasonic treatment for 10 min, it was placed in the XPA-Photochemical Reactor (Xujiang Electromechanical Plant, Nanjing, China), stirred in the dark for 30 min to achieve an adsorption equilibrium, and then switched on 500 W xenon lamp to simulate the solar environment (wavelength: 200–2500 nm) for photocatalytic reaction. 3.4 mL of each sample were collected at regular intervals. After centrifugation, these samples were filtered with a 0.22 μm microporous filter and the supernatant was collected. The concentration of ceftazidime was determined by measuring its absorbance at 255 nm with Agilent UV-Vis 8453 Ultraviolet-visible spectrometer.

**Table 1** Zone of inhibition (mm) of different antibiotics against *E. coli* in absence and in presence of Ag<sub>3</sub>PO<sub>4</sub><sup>a</sup>

Antibiotics (μg per disc)	Inhibition zone diameters (mm)				Increasing rate of inhibition zone area (%)		
	Without Ag <sub>3</sub> PO <sub>4</sub>	Ag <sub>3</sub> PO <sub>4</sub> 0.01 μg per disc	Ag <sub>3</sub> PO <sub>4</sub> 0.1 μg per disc	Ag <sub>3</sub> PO <sub>4</sub> 1 μg per disc	Ag <sub>3</sub> PO <sub>4</sub> 0.01 μg per disc	Ag <sub>3</sub> PO <sub>4</sub> 0.1 μg per disc	Ag <sub>3</sub> PO <sub>4</sub> 1 μg per disc
<b>Aminoglycosides</b>							
Kanamycin 30	21.5	20.3	18.8	21.3	-11	-24	-2
Neomycin 30	19.8	21.3	22.8	19.5	16	33	-3
Amikacin 30	21.5	24.5	24	21.8	27	25	2
Gentamicin 10	17.25	21.5	20.5	19.5	55	41	28
<b>Tetracyclines</b>							
Tetracycline 30	15.5	19.5	17	17	58	20	20
Minocycline 30	14	15.3	16.5	17.3	19	39	52
<b>Quinolones</b>							
Norfloxacin 10	26	28.8	29.3	28.3	22	27	18
Ofloxacin 5	29.5	31	31	31	10	10	10
Ciprofloxacin 5	29	29.8	31	32	5	14	22
<b>Penicillins</b>							
Piperacillin 100	23.1	24.9	25.8	27.3	16	24	39
Ampicillin 10	11	10	11	9	-17	0	-33
Carbenicillin 100	23.8	27.5	26.5	25	34	24	11
<b>Cephalosporin</b>							
Ceftazidime 30	19.25	27.25	29.25	22.5	100	131	37
Cefradine 30	16.8	19.3	18.3	17.5	32	19	-8
Ceftriaxone 30	29.8	34.5	29.8	33	34	0	23
Cefazolin 30	25.5	25.3	25.5	27	-2	0	12
<b>Cefuroxime</b>							
Cefuroxime 30	20	21.5	22	21.5	16	21	16
Cefoperazone 75	27.5	31.8	28.3	29	33	6	11
Cephalexin 30	21	19.3	21.8	21	-16	7	0
<b>Others</b>							
Chloramphenicol 30	23.5	27	22.25	27	32	-10	32
Polymyxin B 300	16.25	16	16	11.25	-3	-3	-52
Furazolidone 300	20.8	24	22.3	22.5	34	15	18

<sup>a</sup> All experiments were done in triplicate, and standard deviations were negligible. The inhibition zone diameter of Ag<sub>3</sub>PO<sub>4</sub> alone is 7 mm.






Fig. 1 XRD pattern of  $\text{Ag}_3\text{PO}_4$ .

## Results and discussion

### The cooperative antibacterial effects

Disk diffusion test was used to study the combined antibacterial activity of  $\text{Ag}_3\text{PO}_4$  and 22 kinds of antibiotics against *E. coli*. The results show that  $\text{Ag}_3\text{PO}_4$  with gentamicin, tetracycline, minocycline and ceftazidime have better synergistic effect (Table 1). Their maximum inhibition zone increase by 55%, 58%, 52% and 131% respectively. However, when  $\text{Ag}_3\text{PO}_4$  combines with other antibiotics, the inhibition zones do not increase significantly, and even the antagonistic effect is observed for ampicillin (−33%) and polymyxin B (−52%).  $\text{Ag}_3\text{PO}_4$  shows the best synergistic effect on ceftazidime, so their synergistic mechanism was systematically studied. In addition, when Ag nanoparticles were added, the inhibition zone of ceftazidime remains unchanged, indicating that they could not produce synergistic effect (Table S1†).

### Characterization of the antibacterial systems

XRD analysis of  $\text{Ag}_3\text{PO}_4$  (Fig. 1) reveals a cubic crystal structure (JCPDS no. 06-0505), no other miscellaneous peaks appears, demonstrating the formation of pure  $\text{Ag}_3\text{PO}_4$  crystals. As shown in Fig. 2,  $\text{Ag}_3\text{PO}_4$  particles have an irregular spherical shape, particle size distribution is between 400 to 800 nm, with an average size of about 650 nm. The mean zeta potential of  $\text{Ag}_3\text{PO}_4$  and  $\text{Ag}_3\text{PO}_4$ -CAZ complexes in distilled water is −40.2 mV and −44.2 mV, the increased number of negative charges is due to  $\text{COO}^-$  on ceftazidime. The surface charge is an important factor in influencing the particles to “see” and react to the cells.<sup>27</sup>




Fig. 2 SEM images of  $\text{Ag}_3\text{PO}_4$ .




Fig. 3 XPS images of  $\text{Ag}_3\text{PO}_4$  with ceftazidime.

### The interaction between antibiotics and inorganic particles

The content of ceftazidime on the surface of  $\text{Ag}_3\text{PO}_4$  was analyzed by XPS. The results (Fig. 3) demonstrate the existence of Ag, P, C, O and N elements. Comparing of the signal intensity of N with Ag, the molar ratio of ceftazidime molecules to Ag atoms in  $\text{Ag}_3\text{PO}_4$ -CAZ is 0.03.  $\text{Ag}_3\text{PO}_4$  takes negative charges, so that the amino groups in ceftazidime determine its adsorption capacity on the surface of  $\text{Ag}_3\text{PO}_4$ . For further investigating their bonding type, the infrared spectra were analyzed. In Fig. 4, the absorption bands at  $556\text{ cm}^{-1}$  and  $1015\text{ cm}^{-1}$  are the characteristic peaks of  $\text{Ag}_3\text{PO}_4$  due to the vibrations of  $\text{PO}_4^{3-}$  groups. The characteristic peaks of ceftazidime appear at  $1759\text{ cm}^{-1}$  and  $1709\text{ cm}^{-1}$  due to the stretching vibrations of four-membered lactam carbonyl and secondary amide carbonyl groups. The N-H bending vibrations are observed at  $1620\text{ cm}^{-1}$ . The band at  $1531\text{ cm}^{-1}$  is due to torsional vibrations of aromatic ring. Compared with the single infrared spectra, there are no obvious changes in characteristic peaks of  $\text{Ag}_3\text{PO}_4$ -CAZ spectrum, indicating that the combination of  $\text{Ag}_3\text{PO}_4$  and ceftazidime is a physical effect and no chemical bond is formed or




Fig. 4 Infrared spectra of  $\text{Ag}_3\text{PO}_4$  with ceftazidime.






Fig. 5 SPR curves of  $\text{Ag}_3\text{PO}_4$ ,  $\text{Ag}_3\text{PO}_4$ -CAZ with *E. coli*.

dissociated, thus no chemical reaction occurs. Therefore, it can be considered that the synergistic effect of  $\text{Ag}_3\text{PO}_4$  with ceftazidime is not due to the formation of new compounds.

#### The interaction of antibacterial agents and bacteria

SPR biosensor was used to study how the adsorption of ceftazidime on  $\text{Ag}_3\text{PO}_4$  affects the interaction between  $\text{Ag}_3\text{PO}_4$  and bacteria. SPR biosensor is commonly used to detect the interaction of biological macromolecules in real time. We extended its function<sup>24</sup> to determine the interaction between nanoparticles and organisms dynamically and quantitatively. As shown in Fig. 5, the ascending curves represent the binding process, the faster the curve rises, the faster the combination, and the greater the association constant ( $K_a$ ). The descending curves indicate dissociation process, the faster the curve drops, the faster the dissociation, and the larger the dissociation constant ( $K_d$ ). The equilibrium dissociation constant ( $K_D$ ) was




Fig. 6 SEM images of *E. coli* treated by (a and b) negative control, (c and d)  $10 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , (e and f)  $10 \text{ mg L}^{-1}$  ceftazidime, (g and h)  $10 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$  and  $10 \text{ mg L}^{-1}$  ceftazidime, (i and j)  $100 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , (k and l)  $100 \text{ mg L}^{-1}$  ceftazidime, (m and n)  $100 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$  and  $100 \text{ mg L}^{-1}$  ceftazidime, (o and p)  $1000 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , (q and r)  $1000 \text{ mg L}^{-1}$  ceftazidime, (s and t)  $1000 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$  and  $1000 \text{ mg L}^{-1}$  ceftazidime.






Fig. 7 Permeability of bacterial cell membrane probed by PI (concentration units are  $\text{mg L}^{-1}$ ).

calculated by the ratio of  $K_d$  to  $K_a$ . Smaller  $K_D$  value indicates stronger affinity and less dissociation, which means a greater interaction force. The  $K_D$  values of *E. coli* with  $\text{Ag}_3\text{PO}_4$  and  $\text{Ag}_3\text{PO}_4$ -CAZ are  $4.17 \text{ mg L}^{-1}$  and  $3.92 \text{ mg L}^{-1}$ , suggesting that the interaction of bacteria with  $\text{Ag}_3\text{PO}_4$ -CAZ is slightly stronger than  $\text{Ag}_3\text{PO}_4$ , though the  $\text{Ag}_3\text{PO}_4$  surface negative charges increase due to its combination with ceftazidime, resulting in the increase of electrostatic repulsion between particles and bacteria. However, because of biochemical reaction between ceftazidime and trans-peptidase in cell wall, the increase of chemical force is more pronounced than electrostatic repulsion.

The SEM analysis<sup>28,29</sup> was used to study the impact of changes in the interaction between nanoparticles and bacteria on membrane morphology of the bacteria. As shown in Fig. 6d, j and p, while the concentration of  $\text{Ag}_3\text{PO}_4$  increased from




Fig. 8 EPR images of  $\text{Ag}_3\text{PO}_4$  in the dark and light.




Fig. 9 Intracellular reactive oxygen species (ROS) probed by DCFH-DA (concentration units are  $\text{mg L}^{-1}$ ).

$10 \text{ mg L}^{-1}$  to  $1000 \text{ mg L}^{-1}$ , the cell wall damage aggravated, and pits appear in the center of the bacteria. When  $\text{Ag}_3\text{PO}_4$  is combined with ceftazidime, cell wall breakage is worse than that of bacteria treated with drugs alone. As seen in Fig. 6j, l and n, when  $100 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$  combined with  $100 \text{ mg L}^{-1}$  ceftazidime, there are obvious holes in the cell wall. Comparing with Fig. 6h, n and t, it is found that as the concentration of the combination drug increases, the pore size on the cell wall gradually increases, and no obvious hole was observed in the bacteria under the action of  $10 \text{ mg L}^{-1}$  combined drug, while the cell wall completely collapsed after treated with  $1000 \text{ mg L}^{-1}$  combined drug.

The cell permeability was analyzed by propidium iodide (PI) stain.<sup>30,31</sup> As shown in Fig. 7, when  $100 \text{ mg L}^{-1}$  CAZ combined with  $10 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , cell permeability increases




Fig. 10 The dissolution of  $\text{Ag}_3\text{PO}_4$  in LB broth with or without ceftazidime.






Fig. 11 The photocatalytic degradation of ceftazidime by  $\text{Ag}_3\text{PO}_4$  under simulated solar radiation.

62.6% than  $100 \text{ mg L}^{-1}$  CAZ. Most obviously, when  $10 \text{ mg L}^{-1}$  CAZ combined with  $100 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , cell permeability increases 80.2% than  $10 \text{ mg L}^{-1}$  CAZ. CAZ can inhibit transpeptidase and interfere with bacterial cell wall synthesis, resulting in increased interaction between  $\text{Ag}_3\text{PO}_4$  and bacteria, as well as increased the membrane damage and the cell permeability.

#### The study of ROS generated by $\text{Ag}_3\text{PO}_4$ , intracellular ROS levels and silver ions release

To further investigate the synergistic mechanisms, the ROS generated by  $\text{Ag}_3\text{PO}_4$ , intracellular ROS levels<sup>32,33</sup> and silver ions release<sup>34</sup> were tested. EPR is a commonly used method<sup>28</sup> for detecting ROS produced by semiconductor materials in a solution environment. Unpaired electrons of different free radicals can be captured by trapping agent DMPO, causing a change in field intensity. As shown in Fig. 8,  $\text{Ag}_3\text{PO}_4$  suspension is not able to produce free radical signals in the dark (*i.e.* antibacterial experimental conditions). However, after irradiation with a 500 W xenon lamp for 20 minutes, a 1 : 2 : 2 : 1 hydroxyl radical signal appears. Therefore, it can be concluded that light irradiation can make

$\text{Ag}_3\text{PO}_4$  produce ROS, which is beneficial to its subsequent photocatalytic degradation of antibiotic residues. In the antibacterial experiment (in the dark), although  $\text{Ag}_3\text{PO}_4$  itself does not produce ROS, it can cause an increase in the intracellular ROS levels. When *E. coli* cells were treated by  $10 \text{ mg L}^{-1}$  and  $100 \text{ mg L}^{-1}$   $\text{Ag}_3\text{PO}_4$ , intracellular ROS levels increased by 23% and 60% (Fig. 9). Besides, the addition of antibiotics makes no difference to ROS levels.

The solubility of  $\text{Ag}_3\text{PO}_4$  in LB broth is shown in Fig. 10. The dissolution rate of  $\text{Ag}_3\text{PO}_4$  alone increases from 0.12% to 1.32% when soaked from 0.5 h to 24 h. In the presence of ceftazidime, it increases from 0.12% to 1.44%. It is found that the addition of antibiotics has little effect on  $\text{Ag}_3\text{PO}_4$  solubility. Therefore, the synergistic mechanisms between them cannot be explained by more silver ions release when antibiotics were added.

#### Photocatalytic degradation of ceftazidime residues

After ceftazidime fulfilled its antibacterial mission, the photocatalytic degradation of CAZ by  $\text{Ag}_3\text{PO}_4$  under simulated solar radiation was conducted to eliminate environment pollution. As shown in Fig. 11, after 2 h of simulated sun exposure in presence of  $1 \text{ g L}^{-1}$   $\text{Ag}_3\text{PO}_4$ ,  $16 \text{ mg L}^{-1}$  CAZ degrades by 75.6% and  $32 \text{ mg L}^{-1}$  CAZ degrades by 71.2%. CAZ degradation slows down between two and four hours.  $\text{Ag}_3\text{PO}_4$  has different degradation efficiencies for different types of antibiotics, it could remove about 30% of ciprofloxacin after 2.5 h,<sup>35</sup> 72% of tetracycline after 1 h,<sup>36</sup> 87% of sulfamethazine and 73% of cloxacillin after 1.5 h<sup>37</sup> under visible light irradiation. Combining the synergistic antibacterial activity with the successive highly photocatalytic degradation of CAZ, the non-polluting nanotechnology for CAZ using nano- $\text{Ag}_3\text{PO}_4$  was established.

## Conclusions

$\text{Ag}_3\text{PO}_4$  exhibits the best synergistic effect on ceftazidime against *E. coli* among 22 antibiotics and can further photocatalytically remove the residues. This non-polluting antibacterial nanotechnology is expected to benefit human health and the water environment. XPS and IR tests indicated that ceftazidime binded to the surface of  $\text{Ag}_3\text{PO}_4$  by non-chemical bond forces. SPR experiments showed that the adsorption of




Fig. 12 Schematic drawing of the synergistic mechanisms of  $\text{Ag}_3\text{PO}_4$  with ceftazidime against *Escherichia coli*.



ceftazidime on the surface of  $\text{Ag}_3\text{PO}_4$  produced a stronger interaction between  $\text{Ag}_3\text{PO}_4$  and bacteria. SEM and PI dye tests further showed that  $\text{Ag}_3\text{PO}_4$  combined with ceftazidime caused more serious damage to cell wall and greater cell permeability (Fig. 12). In addition,  $\text{Ag}_3\text{PO}_4$  produced very low levels of ROS and  $\text{Ag}^+$ , so their contributions to antimicrobial activities were almost negligible. The application of nanotechnology in the field of biomedicine is expected to provide strong protection against infection treatment.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work is supported by the National Natural Science Foundation of China (no. 51771138, 21471114, 21671132), the State Major Research Plan (973) of China (no. 2011CB932404).

## References

- 1 A. Fleming, *Bull. W. H. O.*, 2001, **79**, 780–790.
- 2 E. D. Brown and G. D. Wright, *Nature*, 2016, **529**, 336–343.
- 3 R. Laxminarayan, P. Matsoso, S. Pant, C. Brower, J. Rottingen, K. Klugman and S. Davies, *Lancet*, 2016, **387**, 168–175.
- 4 M. Qiao, G. Ying, A. C. Singer and Y. Zhu, *Environ. Int.*, 2018, **110**, 160–172.
- 5 S. Singh, R. K. Gundampati, K. Mitra, K. Ramesh, M. V. Jagannadham, N. Misra and B. Ray, *RSC Adv.*, 2015, **5**, 81994–82004.
- 6 L. Wang, C. Hu and L. Shao, *Int. J. Nanomed.*, 2017, **12**, 1227–1249.
- 7 P. K. Mishra, H. Mishra, A. Ekielski, S. Talegaonkar and B. Vaidya, *Drug Discovery Today*, 2017, **22**, 1825–1834.
- 8 P. Li, J. Li, C. Z. Wu, Q. S. Wu and J. Li, *Nanotechnology*, 2005, **16**, 1912–1917.
- 9 K. Zheng, M. I. Setyawati, T. Lim, D. T. Leong and J. Xie, *ACS Nano*, 2016, **10**, 7934–7942.
- 10 L. Zou, J. Lu, J. Wang, X. Ren, L. Zhang, Y. Gao, M. E. Rottenberg and A. Holmgren, *EMBO Mol. Med.*, 2017, **9**, 1165–1178.
- 11 H. Deng, D. McShan, Y. Zhang, S. S. Sinha, Z. Arslan, P. C. Ray and H. Yu, *Environ. Sci. Technol.*, 2016, **50**, 8840–8848.
- 12 P. Prema, S. Thangapandiyam and G. Immanuel, *Carbohydr. Polym.*, 2017, **158**, 141–148.
- 13 J. J. Buckley, A. F. Lee, L. Olivi and K. Wilson, *J. Mater. Chem.*, 2010, **20**, 8056–8063.
- 14 D. Chudobova, L. Nejdil, J. Gumulec, O. Krystofova, M. A. M. Rodrigo, J. Kynicky, B. Ruttkay-Nedecky, P. Kopel, P. Babula, V. Adam and R. Kizek, *Int. J. Mol. Sci.*, 2013, **14**, 13592–13614.
- 15 D. J. Martin, G. Liu, S. J. A. Moniz, Y. Bi, A. M. Beale, J. Ye and J. Tang, *Chem. Soc. Rev.*, 2015, **44**, 7808–7828.
- 16 X. Chen, Y. Dai and X. Wang, *J. Alloys Compd.*, 2015, **649**, 910–932.
- 17 A. Wu, C. Tian, W. Chang, Y. Hong, Q. Zhang, Y. Qu and H. Fu, *Mater. Res. Bull.*, 2013, **48**, 3043–3048.
- 18 J. Liu, C. Luo, J. Wang, X. Yang and X. Zhong, *CrystEngComm*, 2012, **14**, 8714–8721.
- 19 X. Xie, C. Mao, X. Liu, L. Tan, Z. Cui, X. Yang, S. Zhu, Z. Li, X. Yuan, Y. Zheng, K. W. K. Yeung, P. K. Chu and S. Wu, *ACS Cent. Sci.*, 2018, **4**, 724–738.
- 20 L. Liu, J. Liu and D. D. Sun, *Catal. Sci. Technol.*, 2012, **2**, 2525–2532.
- 21 S. Huang, Y. Xu, Q. Liu, T. Zhou, Y. Zhao, L. Jing, H. Xu and H. Li, *Appl. Catal., B*, 2017, **218**, 174–185.
- 22 L. Gan, L. Xu and K. Qian, *Mater. Des.*, 2016, **109**, 354–360.
- 23 X. Chen, R. Li, X. Pan, X. Huang and Z. Yi, *Chem. Eng. J.*, 2017, **320**, 644–652.
- 24 T. Yan, J. Tian, W. Guan, Z. Qiao, W. Li, J. You and B. Huang, *Appl. Catal., B*, 2017, **202**, 84–94.
- 25 Z. Yi, J. Ye, N. Kikugawa, T. Kako, S. Ouyang, H. Stuart-Williams, H. Yang, J. Cao, W. Luo, Z. Li, Y. Liu and R. L. Withers, *Nat. Mater.*, 2010, **9**, 559–564.
- 26 Y. Zhang, L. Wang, X. Xu, F. Li and Q. Wu, *Nanomedicine*, 2018, **13**, 339–351.
- 27 K. W. Powers, S. C. Brown, V. B. Krishna, S. C. Wasdo, B. M. Moudgil and S. M. Roberts, *Toxicol. Sci.*, 2006, **90**, 296–303.
- 28 Y. H. Leung, A. M. C. Ng, X. Xu, Z. Shen, L. A. Gethings, M. T. Wong, C. M. N. Chan, M. Y. Guo, Y. H. Ng, A. B. Djuricic, P. K. H. Lee, W. K. Chan, L. H. Yu, D. L. Phillips, A. P. Y. Ma and F. C. C. Leung, *Small*, 2014, **10**, 1171–1183.
- 29 I. N. Ghosh, S. D. Patil, T. K. Sharma, S. K. Srivastava, R. Pathania and N. K. Navani, *Int. J. Nanomed.*, 2013, **8**, 4721–4731.
- 30 Y. Gao, J. Wu, X. Ren, X. Tan, T. Hayat, A. Alsaedi, C. Cheng and C. Chen, *Environ. Sci.: Nano*, 2017, **4**, 1016–1024.
- 31 J. Ruben Morones-Ramirez, J. A. Winkler, C. S. Spina and J. J. Collins, *Sci. Transl. Med.*, 2013, **5**, 190ra81.
- 32 L. Ma, J. Wu, S. Wang, H. Yang, D. Liang and Z. Lu, *J. Inorg. Biochem.*, 2017, **168**, 38–45.
- 33 J. H. Priester, A. Singhal, B. Wu, G. D. Stucky and P. A. Holden, *Analyst*, 2014, **139**, 954–963.
- 34 T. Wu, C. Liu, B. Kong, J. Sun, Y. Gong, K. Liu, J. Xie, A. Pei and Y. Cui, *ACS Cent. Sci.*, 2019, **5**, 719–726.
- 35 Y. Liu, Q. Wu and Y. Zhao, *Dalton Trans.*, 2017, **46**, 6425–6432.
- 36 L. Xie, Z. Yang, W. Xiong, Y. Zhou, J. Cao, Y. Peng, X. Li, C. Zhou, R. Xu and Y. Zhang, *Appl. Surf. Sci.*, 2019, **465**, 103–115.
- 37 B. Shao, X. Liu, Z. Liu, G. Zeng, Q. Liang, C. Liang, Y. Cheng, W. Zhang, Y. Liu and S. Gong, *Chem. Eng. J.*, 2019, **368**, 730–745.

